Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Policy & Regulation
Trends & Finance
Stock: Page 3
Danaher Q2 diagnostics revenues rise 9%
By
LabPulse.com staff writers
For the quarter ended July 1, the company said its overall revenues, including revenues for its diagnostics, life sciences, and environmental and applied solutions divisions, rose 7% year-over-year to $7.75 billion from $7.22 billion, well ahead of Wall Street analysts' average estimate of $7.3 billion.
July 20, 2022
LumiraDx announces proposed share offering
By
LabPulse.com staff writers
The London-based firm also intends to grant underwriters a 30-day option to purchase up to an additional six million common shares at the public offering price.
July 18, 2022
Centogene Q1 year-over-year revenues rise 3%
By
LabPulse.com staff writers
The Rostock, Germany-based firm posted Q1 diagnostics segment revenues of 7.1 million euros, up 11% compared to 6.4 million euros in the prior year's corresponding quarter. The increase in diagnostic segment revenues was mainly due to an 18% year-over-year revenue rise for whole exome sequencing and whole genome sequencing, the firm said.
July 14, 2022
Quotient discloses underwritten public offering price
By
LabPulse.com staff writers
The company said the aggregate net proceeds to Quotient from this offering are expected to be approximately $18.5 million. The company also offered all of the securities sold. Furthermore, Quotient granted the underwriters a 30-day option to purchase up to an additional 10,000,000 of its ordinary shares. The company said that it plans to use net proceeds to fund the ongoing development and commercialization of its MosaiQ microarray menu. It added that funds will go toward working capital, operating expenses, and other general corporate purposes.
June 23, 2022
Sophia names Ken Freedman as chief revenue officer
By
LabPulse.com staff writers
Previously, Freedman was executive vice president of sales for Naviga, where he grew revenue streams, built processes, and helped customers from Canada to Latin America find success, the company said.
January 26, 2022
Lucid closes Nasdaq initial public offering
By
LabPulse.com staff writers
It closed 5 million shares of common stock at a price to the public of $14 per share for total gross proceeds of $70 million before deducting underwriting discounts and commissions and estimated offering expenses.
October 19, 2021
Lucid Diagnostics files for IPO on Nasdaq exchange
By
LabPulse.com staff writers
The number of shares to be offered and the price range for the offering have not yet been determined. Lucid is a majority-owned subsidiary of interventional medical device developer PAVmed.
September 22, 2021
Ortho files for IPO to sell 70M shares
By
LabPulse.com staff writers
Ortho said it plans to grant the IPO's underwriters a 30-day option to purchase up to 10.5 million additional shares at the offering's price, minus underwriting discounts and commissions. The company said it planned to use proceeds from the IPO for working capital and general corporate use, as well as to retire $160 million senior notes due in 2025 and $270 million in senior notes due in 2028.
January 18, 2021
Siemens revenue falls 7% in third quarter
By
LabPulse.com staff writers
For the period (end-June 30), Siemens Healthineers posted revenues of 3.312 billion euros ($3.893 billion U.S.), down 7.2% compared with revenues of 3.569 billion ($4.196 billion) in the third quarter of 2019, and down 6.9% after adjusting for currency effects. The company's net income was 271 million euros ($318.6 million), down compared with 353 million euros ($414.9 million) in the corresponding quarter of 2019.
August 2, 2020
Siemens revenue falls 7% in third quarter
By
LabPulse.com staff writers
For the period (end-June 30), Siemens Healthineers posted revenues of 3.312 billion euros ($3.893 billion U.S.), down 7.2% compared with revenues of 3.569 billion ($4.196 billion) in the third quarter of 2019, and down 6.9% after adjusting for currency effects. The company's net income was 271 million euros ($318.6 million), down compared with 353 million euros ($414.9 million) in the corresponding quarter of 2019.
August 2, 2020
Chembio hit with class-action lawsuit over COVID-19 antibody tests
By
LabPulse.com staff writers
Filed by the Portnoy Law Firm, the complaint alleges that Chembio misled investors on the accuracy of its Dual Path Platform (DPP) COVID-19 serological point-of-care-test for detection of immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies. Then in May, Chembio raised approximately $30.8 million in gross proceeds from a public offering, according to the law firm.
July 21, 2020
BD revenues edge up for 2nd quarter
By
LabPulse.com staff writers
For the quarter, BD reported sales of $4.253 billion, up 1.4% from $4.195 billion in the same period of 2019. The company's net income was $183 million, compared with $20 million in the corresponding quarter of 2019.
May 6, 2020
Previous Page
Page 3 of 4
Next Page